GSK620 is a Potent and Orally Active pan-BET-BD2 Inhibitor
The therapeutic potential of extra terminal domain inhibitor (iBET) has increasing studies both in oncology and immunoinflammatory. Moreover, iBETs are actively progressing in the clinic for oncology indications. Nevertheless, there…